Advertisement

Topics

Janus Company Profile

00:54 EDT 25th September 2018 | BioPortfolio

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwavering pursuit of a statistical advantage. Together, however, our goal is to deliver strong, long-term results to our shareholders. Learn more about us and how we invest.

Location

P.O. Box 173375
Denver
Colorado
80217-3375
United States of America

Contact

Phone: 800.525.3713


News Articles [39 Associated News Articles listed on BioPortfolio]

Janus Kinase Inhibitors: Emerging Applications in Dermatology

Learn about the use of Janus kinase inhibitors, which have become promising treatment options for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, and more. S...

Janus Global Operations team clears vital Iraqi road of IEDs

LENOIR CITY, Tenn., Aug. 31, 2018 /PRNewswire/ -- The Janus Global Operations team operating in Iraq on behalf of the U.S. Department of State's Office Read more...

Janus Kinase JAK Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase JAK Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kinase...

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

Janus Kinase 1 JAK1 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1500

Janus Kinase 1 JAK1 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

Pfizer's Xeljanz cleared for ulcerative colitis in Europe

Drug becomes the first oral therapy and Janus kinase (JAK) inhibitor available for UC

FDA approves Pfizer's Xeljanz for ulcerative colitis

The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient population

Author Correction: Chemical Adsorption and Physical Confinement of Polysulfides with the Janus-faced Interlayer for High-performance Lithium-Sulfur Batteries

Drugs and Medications [0 Results]

None

PubMed Articles [93 Associated PubMed Articles listed on BioPortfolio]

Drying mediated orientation and assembly structure of amphiphilic Janus particles.

Amphiphilic Janus particles demonstrate unique assembly structures when dried on a hydrophilic substrate. Particle orientations are influenced by amphiphilicity and Janus balance. A three-stage model ...

Preparation of polymeric Janus microparticles with hierarchically porous structure and enhanced anisotropy.

Anisotropic Janus particles are of great interest for many applications. It is well known that behavior and utility of Janus particles are highly dependent on their chemistry and geometry. Herein, we ...

Simultaneous two drugs release form Janus particles prepared via polymerization-induced phase separation approach.

Seeded emulsion polymerization of 2-dimethylaminoethylamino methacrylate (DMAEMA) was carried out using monodispersed poly(2-hydroxyehtyl methacrylate) (PHEMA) seeds to produce Janus particles. Three ...

Self-propulsion of aluminum particle-coated Janus droplet in alkaline solution.

Janus droplet motion powered by gas bubbles is studied in this paper. The Janus droplets were fabricated by partially covering one side of an oil droplet with aluminum particles under gravity effect. ...

Novel fabrication of polymer/carbon nanotube composite coated Janus paper for humidity stress sensor.

In this work, we constructed a sensing system on Janus paper with hydrophilic side and hydrophobic side via depositing polymer precursor onto one side of qualitative filter paper. Water in humid envir...

Clinical Trials [14 Associated Clinical Trials listed on BioPortfolio]

A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease

Janus stent is the only marketed drug-eluting stent (DES) without polymer coating as yet in China. The goal of this study is to evaluate the efficacy of JANUS (Tacrolimus eluted stent) i...

This is a Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor in Patients With Multiple Myeloma

The purpose of this study is to determine clinical efficacy and safety of INCB018424, a small molecule Janus kinase (JAK) inhibitor, in patients with refractory or relapsed multiple myelom...

Study of Tofacitinib in Refractory Dermatomyositis

The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatom...

The January Application NUtritional Study (JANUS)

Human beings react differently to changes in diet, exercise, and sleep patterns. The goal of this study is to (1) learn how individuals react to lifestyle choices and suggestions by examin...

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to un...

Companies [5 Associated Companies listed on BioPortfolio]

Janus Pharmaceuticals, Inc

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Jap...

Janus

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwaverin...

BioNTech AG

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combin...

BioNTech and Genevant Sciences

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combin...

Blum Capital Partners

Blum Capital Partners, which is headquartered in San Francisco, utilizes private equity and strategic block transactions to invest in both public and private companies.A representative sample of our i...

More Information about "Janus" on BioPortfolio

We have published hundreds of Janus news stories on BioPortfolio along with dozens of Janus Clinical Trials and PubMed Articles about Janus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janus Companies in our database. You can also find out about relevant Janus Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record